Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to 329.55%.

  • Bolt Biotherapeutics' EBITDA Margin rose 9786900.0% to 329.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 825.72%, marking a year-over-year decrease of 1640300.0%. This contributed to the annual value of 820.0% for FY2024, which is 464400.0% up from last year.
  • Latest data reveals that Bolt Biotherapeutics reported EBITDA Margin of 329.55% as of Q3 2025, which was up 9786900.0% from 477.11% recorded in Q2 2025.
  • Over the past 5 years, Bolt Biotherapeutics' EBITDA Margin peaked at 206.37% during Q1 2024, and registered a low of 5401.57% during Q4 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 1142.73% (2023), whereas its average is 1508.42%.
  • Per our database at Business Quant, Bolt Biotherapeutics' EBITDA Margin skyrocketed by 40403400bps in 2022 and then plummeted by -7017300bps in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' EBITDA Margin stood at 5401.57% in 2021, then soared by 75bps to 1361.23% in 2022, then skyrocketed by 38bps to 846.91% in 2023, then plummeted by -54bps to 1308.24% in 2024, then skyrocketed by 75bps to 329.55% in 2025.
  • Its EBITDA Margin stands at 329.55% for Q3 2025, versus 477.11% for Q2 2025 and 908.1% for Q1 2025.